PureTech Health plc (PRTC)
| Market Cap | 353.30M |
| Revenue (ttm) | 6.39M |
| Net Income (ttm) | 50.68M |
| Shares Out | 240.25M |
| EPS (ttm) | 0.20 |
| PE Ratio | 6.97 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,462 |
| Open | 14.64 |
| Previous Close | 14.70 |
| Day's Range | 14.59 - 14.79 |
| 52-Week Range | 13.30 - 24.99 |
| Beta | 0.82 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2025 |
About PRTC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien... [Read more]
Financial Performance
Financial StatementsNews
PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q2 2025 Earnings Call August 28, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior VP of Communications & Head of Investor Relations Eric Elenko - Co...
PureTech Health plc – Half-Year Report
BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit.
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint.
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
BOSTON--(BUSINESS WIRE)--PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases.
PureTech Announces Leadership Transition
BOSTON--(BUSINESS WIRE)--PureTech Announces Leadership Transition.
PureTech Announces Board Change
BOSTON--(BUSINESS WIRE)--PureTech Announces Board Change.
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.
PureTech to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF).
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference.
PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q4 2024 Earnings Call April 30, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior Vice President, Communications Bharatt Chowrira - Chief Executive O...
PureTech Announces Annual Results for Year Ended December 31, 2024
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2024.
PureTech Health: Notice of Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
BOSTON--(BUSINESS WIRE)--PureTech Appoints Peel Hunt as Joint UK Corporate Broker.
PureTech Health plc Statement Regarding Press Speculation
BOSTON--(BUSINESS WIRE)--Statement regarding press speculation.
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair.
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform.
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
BOSTON--(BUSINESS WIRE)--PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML).
PureTech Appoints UBS as UK Corporate Broker
BOSTON--(BUSINESS WIRE)--PureTech Appoints UBS as UK Corporate Broker.
PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
BOSTON--(BUSINESS WIRE)--PureTech's Deupirfenidone Slowed Lung Function Decline in People w/ IPF, Achieving the Primary & Key Secondary Endpoints in ELEVATE IPF Phase 2b Trial.
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024.
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
BOSTON--(BUSINESS WIRE)--PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting.